Predicting and evaluating response to omalizumab in patients with severe allergic asthma
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine
Reference21 articles.
1. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment);Humbert;INNOVATE Allergy,2005
2. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma;Ayres;Allergy,2004
3. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR;Vignola;Allergy,2004
4. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma;Busse;J Allergy Clin Immunol,2001
5. Omalizumab is effective in the long-term control of severe allergic asthma;Lanier;Ann Allergy Asthma Immunol,2003
Cited by 246 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein–protein interaction analyses;Respiratory Research;2023-12-06
2. Biologics for severe asthma and beyond;Pharmacology & Therapeutics;2023-12
3. A robust mRNA signature obtained via recursive ensemble feature selection predicts the responsiveness of omalizumab in moderate‐to‐severe asthma;Clinical and Translational Allergy;2023-11
4. Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient;Respiratory Medicine;2023-11
5. Cost effectiveness of omalizumab for severe asthma in Colombia;Journal of Asthma;2023-10-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3